Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOW-OGESTREL-21 vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive. Suppresses gonadotropin release (FSH and LH) via estrogen (ethinyl estradiol) and progestin (norgestrel), inhibiting ovulation. Also increases cervical mucus viscosity and alters endometrium.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy
Prevention of pregnancy
One tablet (norgestrel 0.3 mg/ethinyl estradiol 30 mcg) orally once daily for 21 days, followed by 7 pill-free days.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Norgestrel: 18-28 hours; ethinyl estradiol: 13-27 hours. Steady-state achieved after 5-7 days.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Hepatic via CYP3A4 isoenzymes (ethinyl estradiol and norgestrel undergo hydroxylation and conjugation). Enterohepatic circulation.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Ethinyl estradiol and norgestrel are excreted primarily as glucuronide and sulfate conjugates in urine (50-60%) and feces (30-40%).
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Norgestrel: 93-95% (albumin, SHBG); ethinyl estradiol: 97-98% (albumin).
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Norgestrel: 3.5-4.5 L/kg; ethinyl estradiol: 2.5-3.5 L/kg; indicates extensive tissue distribution.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: norgestrel >90%; ethinyl estradiol 40-50% (first-pass metabolism).
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No dosage adjustment required for mild to moderate renal impairment. Use is contraindicated in severe renal impairment or acute renal failure due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Contraindicated in acute or chronic hepatic dysfunction, including Child-Pugh class A, B, or C. Do not use.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Not indicated for use before menarche. For postmenarchal adolescents, use same dosing as adults: one tablet daily for 21 days, then 7 days off.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not indicated for postmenopausal women. No specific geriatric dosing; contraindicated in women over 35 who smoke, and generally avoided in older women due to increased cardiovascular risk.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases risk of serious cardiovascular events (e.g., myocardial infarction, thromboembolism, stroke). Risk increases with age (>35 years) and smoking severity. Women over 35 who smoke should not use this drug.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thromboembolic disorders (venous and arterial),Cerebrovascular disease,Myocardial infarction,Hypertension,Hepatic adenoma or carcinoma,Gallbladder disease,Carbohydrate/lipid metabolism effects,Ocular changes (e.g., retinal thrombosis),Headache/migraine exacerbation,Uterine bleeding irregularities,Fetal development (discontinue if pregnancy suspected),Depression,Contact lens intolerance,Fluid retention,Breast cancer risk (ongoing surveillance),Hereditary angioedema
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Known or suspected pregnancy,Current or history of thrombophlebitis or thromboembolic disorders,Current or history of cerebrovascular or coronary artery disease,Breast cancer or other estrogen-sensitive neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known liver impairment,Major surgery with prolonged immobilization,Diabetes mellitus with vascular involvement,Uncontrolled hypertension,Hypertriglyceridemia,Smoking >15 cigarettes/day and age ≥35,Migraine with focal aura at any age
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
No significant food interactions. Grapefruit juice may slightly increase estrogen exposure but does not require avoidance. Alcohol does not impair contraceptive efficacy but may increase risk of nausea or missed doses.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
Pregnancy category X. Contraindicated in pregnancy. Fetal risk includes cardiovascular anomalies, neural tube defects, and limb reduction defects if exposed during first trimester. Second and third trimester exposure may cause masculinization of female fetuses due to progestin component.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Small amounts of ethinyl estradiol and norgestrel are excreted in human milk. M/P ratio not established. May reduce milk production and composition. Use is generally not recommended during breastfeeding; alternative contraception advised.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Contraindicated in pregnancy; no dose adjustments indicated as drug should not be used. Pharmacokinetic changes in pregnancy (e.g., increased clearance) are not relevant due to contraindication.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
LOW-OGESTREL-21 is a low-dose estrogen-progestin combination oral contraceptive. Its effectiveness may be reduced by concomitant enzyme-inducing drugs (e.g., rifampin, carbamazepine, phenytoin, St. John's wort). Breakthrough bleeding and spotting are more common with low-dose formulations. Contraception is not reliable if two or more active pills are missed; backup contraception is required. Initiation on the first day of menstrual bleeding eliminates need for backup contraception. Advise patients to take pill at same time daily to maintain consistent hormone levels.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one pill daily at the same time, even if you have spotting or bleeding between periods.,If you miss one pill, take it as soon as you remember and continue the next pill at the usual time; no backup is needed.,If you miss two consecutive active pills, take two pills daily for two days, then resume one daily; use backup contraception for 7 days.,Possible side effects include nausea, headache, breast tenderness, and irregular bleeding; these often improve after 3 cycles.,Smoking while using this pill increases risk of serious cardiovascular events; do not smoke if over 35 years old.,Use a backup method (e.g., condoms) until you have taken 7 consecutive active pills if starting for the first time after day 5 of menstrual cycle.,Store pills at room temperature away from moisture.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOW-OGESTREL-21 vs ALYACEN 1/35, answered by our medical review team.
LOW-OGESTREL-21 is a Oral Contraceptive that works by Combination oral contraceptive. Suppresses gonadotropin release (FSH and LH) via estrogen (ethinyl estradiol) and progestin (norgestrel), inhibiting ovulation. Also increases cervical mucus viscosity and alters endometrium.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOW-OGESTREL-21 and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOW-OGESTREL-21 is: One tablet (norgestrel 0.3 mg/ethinyl estradiol 30 mcg) orally once daily for 21 days, followed by 7 pill-free days.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOW-OGESTREL-21 and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOW-OGESTREL-21 is classified as Category C. Pregnancy category X. Contraindicated in pregnancy. Fetal risk includes cardiovascular anomalies, neural tube defects, and limb reduction defects if exposed during first trimester.. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.